Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 2 6Phase 2/3 2Phase 1 2Phase NA 1Phase EARLY_PHASE1 1Phase 4 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Tuberous Sclerosis 1Smith-Magenis Syndrome 1Relapsed Malignant Solid Tumor 1Parasomnias 1Autism Spectrum Disorder 1Angelman Syndrome 1

Interventions

Paclitaxel 292Gemcitabine 254Carboplatin 254Cisplatin 251Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 181Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Temozolomide 110Sorafenib 110Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Pemetrexed 90Ipilimumab 90fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Completed × Melatonin × Clear all
NCT01858155 2019-01-31

Phase I Dose Finding Study for Melatonin in Pediatric Oncology Patients With Relapsed Solid Tumors

C17 Council

Phase 1 Completed
9 enrolled
Other solid neoplasm

Relapsed Malignant Solid Tumor

NCT01903681 2014-04-04

Assessment of the Pharmacokinetics of CircadinĀ® in Children With Neurodevelopmental Disorders and Sleep Disturbances

Neurim Pharmaceuticals Ltd.

Phase 1 Completed
16 enrolled

Autism Spectrum Disorder, Tuberous Sclerosis, Angelman Syndrome, Parasomnias, Smith-Magenis Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚔